Navigation Links
Major EPSRC Programme Grant to support new Oxford Centre for Drug Delivery Devices
Date:5/23/2014

Cancer therapy drugs tend to achieve limited accumulation and poor penetration in tumours, reducing their effectiveness. For many years, the only methods used to improve drug uptake by tumours have been pharmacological, and these have had limited success.

Recent research at Oxford University has shown that physical mechanisms triggered by ultrasound, magnetic fields or shock waves can dramatically improve the delivery and penetration of existing and experimental drugs into tumours.

Now a new research centre, The Oxford Centre for Drug Delivery Devices (OxCD3), will look to exploit engineering approaches, involving a combination of stimulus- responsive nanocarriers and medical devices already in clinical use, to improve the therapeutic outcomes of drug-based cancer treatments.

The new centre will be based at the University of Oxford and has been made possible by a 10.1 million Programme Grant which includes 6.4 million from the Engineering and Physical Sciences Research Council (EPSRC).

Led by Professors Coussios, Stride, Carlisle and Cleveland in the Institute of Biomedical Engineering, OxCD3 represents a partnership between the Department of Engineering Science, the Department of Oncology (Professors Seymour, Sibson and Vallis), the MRC Weatherall Institute of Molecular Medicine (Prof. Rabbitts), the Nuffield Department of Surgical Science (Prof. Friend) and the Clinical Biomanufacturing Facility (Dr Moyle).

The principal investigator, Professor Constantin Coussios, said: "We are very grateful to EPSRC, our industrial partners and the University of Oxford for their support of OxCD3. This will enable the creation of a sustainable, world-‐ unique multi-‐disciplinary environment for combinational engineering of biology, chemistry and medical devices to improve drug delivery under a single roof. It is also expected to create a much-‐needed training environment for the next generation of young scientists working on combination therapies and biomedical nanotechnology, by providing direct exposure to regulatory and manufacturing issues encountered when translating laboratory research into production and clinical practice."

The new Centre will initially focus on improving the delivery of several classes of cancer drugs, ranging from conventional chemotherapy and radiopharmaceuticals to next-‐generation antibodies, viruses and siRNA, from proof-of-concept laboratory studies to manufacture in preparation for clinical trials. The ultimate aim is to establish a centre of excellence for challenging drug delivery applications across a broad range of biological barriers and disease indications beyond cancer.


'/>"/>

Contact: EPSRC Press Office
pressoffice@epsrc.ac.uk
01-793-444-404
Engineering and Physical Sciences Research Council
Source:Eurekalert

Related medicine news :

1. Therapy sought to reduce major risk from minor bleeding that can follow stroke
2. Major lung resection safer than ever, especially at the busiest hospitals
3. Genetic alterations in shared biological pathways as major risk factor for ASD
4. Gen X obesity a major problem for healthcare, workforce
5. Surgery after major stroke also improves survival odds in elderly patients
6. A majority prefers letting computers decide
7. Major third-hand smoke compound causes DNA damage -- and potentially cancer
8. Patient requests for specific drugs have major impact on prescribing, reports study in Medical Care
9. Major League Baseball players win more games following Tommy John surgery
10. NYU researchers find majority of Latinas are unaware of their risk of diabetes
11. International study shows majority of children unaware of cigarette warning labels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology: